Edwards Lifesciences (EW) Non-Current Debt (2009 - 2026)

Edwards Lifesciences' Non-Current Debt history runs 18 years deep, the most recent figure standing at $598.5 million for Q1 2026.

• On a quarterly basis, Non-Current Debt changed 0.12% year-over-year to $598.5 million in Q1 2026; TTM through Mar 2026 was $598.5 million, a 0.12% change from a year earlier, with the FY2025 full-year figure at $598.3 million, changed 0.1% from the prior year.
• Non-Current Debt was little changed at $598.5 million in Q1 2026 per EW's latest filing, from $598.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $598.5 million in Q1 2026 and bottomed at $595.9 million in Q1 2022.
• The 5-year median for Non-Current Debt is $597.2 million (2024), against an average of $597.2 million.
• Across the five-year window, Non-Current Debt advanced 0.12% in 2022 and advanced 0.1% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $596.3 million in 2022, then increased by 0.12% to $597.0 million in 2023, then grew by 0.12% to $597.7 million in 2024, then increased by 0.1% to $598.3 million in 2025, then gained by 0.03% to $598.5 million in 2026.
• Per Business Quant, the three latest EW Non-Current Debt figures stand at $598.5 million (Q1 2026), $598.3 million (Q4 2025), and $598.2 million (Q3 2025).